Healthcare / Pharmaceutical RetailersShenzhen
$18.30
+0.58 (+3.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $410.9M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.3B
P/E
33.9x
↑EV/EBITDA
11.6x
↓ROE
9.1%
↑Gross Margin
33.9%
↓Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.9%
FCF CAGR
+114.8%
FCF margin
12.5%
FCF / Net income
3.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.49B · net income $191.4M · FCF $684.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.49B | $5.49B | $4.53B | $3.80B | $3.26B |
| Net Income | $191.4M | $191.4M | $137.7M | $114.7M | $160.8M |
| EBITDA | $661.2M | $661.2M | $530.0M | $389.3M | $402.6M |
| EPS | 0.48 | 0.48 | 0.34 | 0.29 | 0.47 |
| Gross Margin | 33.9% | 33.9% | 32.6% | 30.6% | 32.6% |
| Operating Margin | 7.5% | 7.5% | 5.7% | 4.8% | 7.5% |
| Net Margin | 3.5% | 3.5% | 3.0% | 3.0% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.64 | 0.64 | 0.65 | 0.69 | 0.80 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $684.3M | $684.3M | $410.9M | $-84.9M | $69.1M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 6.9% | 5.9% | 17.0% |
| Valuation | |||||
| P/E | 33.89 | 33.89 | 30.68 | 54.66 | — |
| EV/EBITDA | 11.63 | 11.63 | 8.54 | 16.10 | — |
| P/B | 3.48 | 3.48 | 2.11 | 3.22 | — |
| Growth & Yield | |||||
| Revenue Growth | 21.1% | 21.1% | 19.3% | 16.4% | — |
| EPS Growth | 41.2% | 41.2% | 17.2% | -38.3% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
50.1%
EPS terminal req.
$1.62
Spread vs growth
-8.9%
5Y implied EPS CAGR
32.6%
EPS terminal req.
$1.96
Spread vs growth
8.6%
10Y implied EPS CAGR
20.8%
EPS terminal req.
$3.16
Spread vs growth
20.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.0%
Start / end P/E
34.6x → 38.1x
EPS bridge
0.34 → 0.48
Residual
+4.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.